Life sciences M&A is back, but not as a free-for-all.
Goodwin positions itself around a clear 2026 market signal: Life sciences M&A has reemerged as a competitive arena after a quieter period. The firm says strategic buyers are competing for next-generation innovation and that companies are increasingly using M&A as a core tool for value creation and liquidity. (Goodwin Law)
The deal list is substantial. Goodwin cites its work on Kelonia Therapeutics’ $7 billion acquisition by Lilly, Tubulis’ acquisition by Gilead for $3.15 billion upfront plus up to $1.85 billion in milestones, Synnovation Therapeutics’ transaction with Novartis for $2 billion upfront plus up to $1 billion in milestones, and Centessa’s agreement to be acquired by Lilly for up to $7.8 billion. (Goodwin Law)
The more interesting point is not simply volume. It is structure. Goodwin highlights regulatory, IP and antitrust diligence, clinical and regulatory milestone-linked CVRs, negotiation strategy and risk allocation. That is where the market is going. Buyers are not just chasing assets. They are trying to de-risk science, protect pipeline strategy and structure around uncertainty.
For corporate counsel and boards, the takeaway is practical. Life sciences M&A in 2026 appears active, but the winning deals will depend on diligence depth, regulatory judgment, IP clarity and transaction architecture. The legal function is not merely papering the deal. It is shaping whether the deal can get signed, survive review and deliver value.
In sectors where innovation is scarce and patent cliffs matter, legal strategy becomes part of capital strategy.
Expect more use of milestone payments, CVRs, antitrust planning and board-level scrutiny of whether target assets can withstand scientific, regulatory and commercial diligence.